WASHINGTON — Danaher Corporation has announced plans to acquire Masimo Corporation in a deal valued at nearly $9.9 billion. The agreement entails purchasing Masimo’s common stock at $180 per share in cash, which highlights both companies’ focus on expanding their reach in the healthcare technology sector.
Danaher, a prominent player in global science and technology, aims to integrate Masimo’s advanced patient monitoring technologies, particularly in pulse oximetry, into its existing diagnostics portfolio. With Masimo’s reputation for innovative healthcare solutions, this acquisition is anticipated to bolster Danaher’s offerings, especially in acute care settings.
Rainer M. Blair, Danaher’s CEO, expressed enthusiasm about the union, stating that Masimo’s distinct technologies and strong brand will significantly enhance their diagnostics division. He noted that the company sees substantial potential for improving patient outcomes and expanding market accessibility through this merger.
Julie Sawyer Montgomery, Danaher’s Executive Vice President for Diagnostics, emphasized the importance of Masimo’s AI-enabled monitoring technologies. She pointed out that integrating these capabilities will not only innovate Danaher’s product line but also assist clinicians in making better-informed decisions during critical patient care situations.
Post-acquisition, Masimo will operate as a standalone entity under Danaher’s Diagnostics segment, joining established brands like Radiometer and Beckman Coulter. This strategy aims to leverage Danaher’s global reach while maintaining the unique identity and operational focus of Masimo.
Financial projections indicate that Masimo could contribute significantly to Danaher’s revenues, with forecasts suggesting an annual earnings increase of up to $0.70 per share by the fifth year following the acquisition. The deal is expected to close in the latter half of 2026, pending regulatory approvals and shareholder consent.
Danaher plans to finance the acquisition using existing cash reserves along with debt financing. Experts predict that this transaction could enhance Danaher’s core revenue growth profile, with Masimo expected to generate over $530 million in earnings before interest, taxes, depreciation, and amortization by 2027.
The strategic maneuvering by Danaher to acquire Masimo underscores a broader trend in the healthcare industry, where companies seek to consolidate expertise and resources to deliver more effective patient care solutions. As healthcare continues to evolve rapidly, the incorporation of enhanced diagnostic technologies will likely play a pivotal role in shaping future practices in the medical field.
This acquisition marks a significant moment for both companies and could set a new standard for innovations in patient care technology. With strong leadership and a clear vision for the future, Danaher is positioning itself as a formidable force in the healthcare marketplace.